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Abstract
Background: Given the predominance of invasive fungal disease (IFD) amongst the non-immunocompromised
adult critically ill population, the potential benefit of antifungal prophylaxis and the lack of generalisable tools to
identify high risk patients, the aim of the current study was to describe the epidemiology of IFD in UK critical care
units, and to develop and validate a clinical risk prediction tool to identify non-neutropenic, critically ill adult
patients at high risk of IFD who would benefit from antifungal prophylaxis.
Methods: Data on risk factors for, and outcomes from, IFD were collected for consecutive admissions to adult,
general critical care units in the UK participating in the Fungal Infection Risk Evaluation (FIRE) Study. Three risk
prediction models were developed to model the risk of subsequent Candida IFD based on information available at
three time points: admission to the critical care unit, at the end of 24 h and at the end of calendar day 3 of the
critical care unit stay. The final model at each time point was evaluated in the three external validation samples.
Results: Between July 2009 and April 2011, 60,778 admissions from 96 critical care units were recruited. In total, 359
admissions (0.6 %) were admitted with, or developed, Candida IFD (66 % Candida albicans). At the rate of
candidaemia of 3.3 per 1000 admissions, blood was the most common Candida IFD infection site. Of the initial 46
potential variables, the final admission model and the 24-h model both contained seven variables while the end of
calendar day 3 model contained five variables. The end of calendar day 3 model performed the best with a c index
of 0.709 in the full validation sample.
Conclusions: Incidence of Candida IFD in UK critical care units in this study was consistent with reports from other
European epidemiological studies, but lower than that suggested by previous hospital-wide surveillance in the UK
during the 1990s. Risk modeling using classical statistical methods produced relatively simple risk models, and
associated clinical decision rules, that provided acceptable discrimination for identifying patients at ‘high risk’ of
Candida IFD.
Trial registration: The FIRE Study was reviewed and approved by the Bolton NHS Research Ethics Committee
(reference: 08/H1009/85), the Scotland A Research Ethics Committee (reference: 09/MRE00/76) and the National
Information Governance Board (approval number: PIAG 2-10(f)/2005).
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Background
Once seen typically in immunocompromised patients, in-
vasive fungal disease (IFD) amongst the critically ill is now
predominantly found in the adult, general, non-
immunocompromised population [1]. Over 5000 cases of
IFD due to Candida species (Candida IFD) occur in the
UK each year, with 40 % occurring in critical care units
[2]. Epidemiological trends in IFD among the critically ill
are changing, due in large part to the increased incidence
of IFD risk factors and to new therapeutic strategies.
A number of randomised controlled trials have evalu-
ated prophylactic and or empiric therapy with antifun-
gals in non-neutropenic, critically ill patients. Despite
patient heterogeneity, these trials have demonstrated a
beneficial effect of antifungal prophylaxis on the risk of
developing proven IFD and suggested a reduction in
mortality [3]. Given that the effectiveness of antifungal
prophylaxis has only been demonstrated in groups at
high risk of IFD and that more widespread use of anti-
fungal drugs may promote resistance and drive up costs,
it is necessary to establish a method to identify high risk
patient groups, who stand to benefit most from an
antifungal prophylactic strategy. Several risk models and
clinical decision rules have been proposed for identifying
patients at high risk of IFD [4–8]. However, model
generalisability has been limited owing to the restricted
study population, being either post-surgical patients [7, 8],
or patients already colonised with Candida [8].
Given the potential benefit of antifungal prophylaxis and
lack of generalisable tools to identify high risk patients, the
aim of the current study was to describe the epidemiology
of IFD in UK critical care units and to develop and validate
a clinical risk prediction tool to predict the risk of Candida
IFD at three decision time points: at admission to the crit-
ical care unit, at 24 h following admission, and at the end
of the third calendar day following admission, in order to
identify non-neutropenic, critically ill adult patients at high
risk of IFD who would benefit from antifungal prophylaxis.
Methods
Study design
Based on the results of a systematic review of the litera-
ture conducted by our research team [5] and on expert
clinical opinion, data on risk factors for, and outcomes from,
IFD were collected for consecutive admissions to adult,
general critical care units in the UK participating in the
Fungal Infection Risk Evaluation (FIRE) Study [9]. These
data were linked with additional patient data collected for
national clinical audits – the Case Mix Programme (in
England, Wales and Northern Ireland) and the Scottish In-
tensive Care Society Audit Group (in Scotland) – to form
the FIRE Study database. For all sources, data were col-
lected prospectively and abstracted by trained data collec-
tors and underwent extensive validation.
FIRE Study database
For all critical care unit admissions, data were extracted on
age, sex, medical history, surgical status, acute severity of
illness, primary reason for admission, therapies received,
IFD, fungal colonisation, mortality and length of stay.
Severe comorbidities were defined using the APACHE
II method [10] and must have been evident in the 6
months prior to critical care unit admission. Surgery
within up to 7 days prior to admission to the critical
care unit was classified as either emergency/urgent or
scheduled/elective. Acute severity of illness was sum-
marised using the APACHE II Score [10] and the
ICNARC Physiology Score [11] assessed during the first
24 h following admission to the critical care unit.
Data on the following therapies were collected: total
parenteral nutrition; systemic antimicrobials; immuno-
suppressive therapy; central venous catheters, organ sup-
port; and antifungal use. Corticosteroids were included
as immunosuppressives. Organ support was recorded
throughout the critical care unit stay, defined according
to the UK Department of Health Critical Care Minimum
Dataset [12].
Fungal colonisation was defined as the presence of
yeasts in any sample reported on a microbiology system
and was recorded as the date that a positive report was
available – i.e. the point at which a treatment decision
could be made based on this knowledge.
IFD was defined as a blood culture or sample from a
normally sterile site (including, but not restricted to:
cerebrospinal fluid; peritoneal fluid; pleural fluid; and
pericardial fluid; and excluding bronchoalveolar lavage,
urine and sputum) positive for yeast/mould cells in a
microbiological or histopathological report. This defin-
ition was based on the Revised Definitions of Invasive
Fungal Disease from the European Organization for Re-
search and Treatment of Cancer/Invasive Fungal Infec-
tions Cooperative Group and the National Institute of
Allergy and Infectious Diseases Mycoses Study Group
(EORTC/MSG) Consensus Group [13]. This definition
was chosen to best capture Candida IFD and was recog-
nised to under-represent IFD due to other species. Tim-
ing of IFD was defined by the date on which the positive
sample was collected. All patients reported to have IFD
(pre critical care unit or during critical care unit stay),
and a random sample of 2 % of those reported not to
have IFD, were independently rechecked against hospital
notes and microbiology records by the local investigator,
blinded to the original data. For admissions that devel-
oped IFD during critical care unit stay, the timing of the
first systemic antifungal was also reported relative to the
timing of IFD.
Patients were followed up for mortality and length of
stay until death or final discharge from acute hospital
and those transferred to another acute hospital.
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Descriptive epidemiology
Analyses were performed using Stata/SE Version 10.1
(StataCorp LP, College Station TX). For the purpose
of summarising case mix, outcomes and antifungal
use, the cohort was divided into groups of: admis-
sions with IFD positive for Candida albicans (Can-
dida albicans IFD); admissions with IFD positive for
other Candida species (non-albicans Candida spp
IFD); and admissions with no IFD either prior to or
during the critical care unit stay (no IFD). Admissions
with IFD positive for Candida of unknown species or
non-Candida species were excluded due to small
numbers. Admissions with IFD positive for both Can-
dida albicans and non-albicans Candida species were
included in the Candida albicans subgroup.
Development and validation of risk prediction models
Three risk prediction models were developed to model
the risk of subsequent Candida IFD based on informa-
tion available at three time points: admission to critical
care unit, at the end of 24 h and at the end of calendar
day 3 of the critical care unit stay.
The following exclusions were applied for the develop-
ment and validation of the risk model at admission: age
less than 18 years; second and subsequent admissions of
the same patient; neutropenia (absolute neutrophil count
less than 1 × 109 l−1); active haematological malignancy;
admission following solid organ transplant; IFD identified
up to 7 days prior to admission; and receipt of systemic
antifungals up to 7 days prior to admission.
For the models at 24 h and at the end of calendar day
3, exclusions were as above plus any of the following oc-
curring before the decision time point: death or dis-
charge from the critical care unit; IFD; or receipt of
systemic antifungals.
The dataset was divided into the following develop-
ment and validation samples: development sample – all
admissions to a random sample of participating critical
care units in England, Wales and Northern Ireland, July
2009 to December 2010 (selected to include approxi-
mately two thirds of all admissions); random validation
sample – all admissions to the remaining units in Eng-
land, Wales and Northern Ireland; temporal validation
sample – all admissions to units in the development
sample, January to March 2011; and geographical valid-
ation sample – all admissions to units in Scotland.
The risk prediction models were derived in the devel-
opment sample using logistic regression models with ro-
bust standard errors to allow for clustering within
critical care units. All candidate variables were included
in a ‘full’ multivariable model and the model was pro-
gressively simplified using backwards-stepwise selection
with the least statistically significant being removed at
each step.
Model discrimination was assessed with the c index
[14], equivalent to the area under the receiver operating
characteristic curve [15], calibration by graphical plots of
observed against expected risk, and overall fit by Brier’s
score [16], the mean squared error between outcome
and prediction. Bootstrapping with 200 bootstrap sam-
ples was used on the development sample to internally
validate the final selected model at each time point and
to estimate optimism adjusted measures of the model
discrimination and overall fit [17]. The final model at
each time point was evaluated in the three external val-
idation samples: a random sample, a geographic sample
and a temporal sample, as described above. Each sample
was chosen to test different aspects of future perform-
ance. The models were evaluated in each validation sam-
ple separately and then in all three samples combined
using the same measures as in the development sample.
The sensitivity, specificity, positive predictive value
and negative predictive value of the risk model at the
end of calendar day 3 was compared with that of exist-
ing clinical decision rules identified from the systematic
review of the literature using the full validation dataset.
For comparison with the clinical decision rules, three al-
ternative risk thresholds were applied to the risk predic-
tions from the FIRE Study model corresponding to
predicted risks of >0.5 % (F1), >1 % (F2) and >2 % (F3).
The following existing clinical decision rules were in-
cluded in the comparison: three rules presented in
Ostrosky-Zeichner et al. [6] (OZ1-OZ3) and three rules
presented in Paphitou et al. [7] (P1-P3).
Results
Between July 2009 and April 2011, a total of 96 critical
care units with 60,778 admissions participated in the
FIRE Study (see Fig. 1). The units were representative of
all UK adult general critical care units in terms of geo-
graphical distribution, hospital teaching status and num-
ber of beds.
In total, 359 admissions (0.6 %) were admitted with, or
developed, Candida IFD of which 66 % were Candida
albicans (see Fig. 2). The most common non-albicans
Candida species was Candida glabrata (17 %).
Admissions with non-albicans Candida spp IFD were
compared to admissions with Candida albicans IFD as
shown in Table 1. The critical care unit and acute hos-
pital lengths of stay and mortality rates were comparable
between the Candida albicans and non-albicans Can-
dida spp. IFD subgroups but substantially higher when
compared with admissions with no IFD. Overall crude
critical care unit and acute hospital mortality for admis-
sions with any Candida species IFD were 29.9 and
39.6 %, respectively.
The most common Candida IFD infection site was
blood (57 %; Additional file 1: Table S1) corresponding
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to a rate of candidaemia of 3.3 per 1000 admissions. Of
the 359 total admissions with IFD, approximately half
had pre-critical care unit IFD (identified from a sample
taken pre-admission or on calendar day 1 or 2) with the
other half developing IFD during their critical care unit
stay (identified from a sample taken from calendar day 3
onwards; Additional file 2: Figure S1). The median day
for Candida IFD developed during the critical care unit
stay was day 7 (IQR 4 to 12). The incidence of Candida
IFD developed during the critical care unit stay was 3.1
cases per 1000 admissions.
Both Candida spp. IFD subgroups received similar
organ support and systemic antifungals (Additional file
3: Table S2). In the admissions with Candida IFD that
received systemic antifungals, 27 % received these before
the first sample from which IFD was identified, 47 %
within 3 days of the first positive sample and 27 % more
than 3 days after the first positive sample.
Characteristics of the patients included in the develop-
ment and validation samples are reported in the
Additional file 4: Table S3. Of 46 potential variables, 19
candidate variables were selected for the admission
model and, following backwards elimination, the final
model contained seven variables with 11 parameters
(c index 0.705; Table 2 and Additional file 5: Table S4). The
24-h model contained seven variables with 10 parameters
Descriptive epidemiology of IFDa
All admissions to 96 adult, 
general critical care units
(60,778)
Candida albicans IFD
(235)
Non-albicans 
Candida spp IFD
(106)
No IFD
(60,362)
Included in development of 
risk model at admission
(D: 35,455, V: 18,834)
Included in development of 
risk model at end of day 3
(D: 16,405, V: 8,488)
Included in development of 
risk model at 24h
(D: 26,540, V: 13,862)
Exclusions:
Age < 18 years (883)
Readmission (2,536)
Neutropenia (1,377)
Haematological malignancy (678)
Solid organ transplant (372)
IFD pre-admission (65)
Systemic antifungal pre-admission (578)
Exclusions:
Death by 24h (2,635)
Discharge by 24h (10,472b)
IFD identified by 24h (44)
Systemic antifungal by 24h (736)
Exclusions:
Death by day 3 (1,849)
Discharge by day 3 (13,314)
IFD identified by day 3 (25)
Systemic antifungal by day 3 (321)
Fig. 1 Flow of admissions in the FIRE Study
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(c index 0.824) and the end of calendar day 3 model con-
tained five variables with seven parameters (c index 0.835).
Validation of the models is reported in Table 3. The end of
calendar day 3 model performed the best with a c index of
0.709 in the full validation sample.
The comparison of clinical decision rules based on the
end of calendar day 3 FIRE Study model with existing
clinical decision rules is reported in Table 4. The best
performing of the existing rules was rule OZ3. This rule
had better sensitivity, specificity, PPV and NPV than
rules P1 and P3, while the remaining rules (OZ1, OZ2
and P2) gave higher sensitivity but at the cost of treating
43 to 83 % of admissions. Applying thresholds of >0.5 %
(F1) or >1 % (F2) to risk predictions from the FIRE
Study model gave similar performance to rule OZ3, with
rule F1 giving slightly higher sensitivity but lower speci-
ficity and rule F2 giving slightly lower sensitivity but
higher specificity (Additional file 6: Figure S2).
Discussion
The FIRE Study is the first multicentre study to report
specifically on Candida IFD in UK critical care units
and to develop and validate risk prediction tools to iden-
tify critically ill non-neutropenic adults at risk for IFD.
Candida albicans accounted for two thirds of Candida
IFD. Blood was the most common infection site, ac-
counting for more than half of all Candida IFD. The risk
prediction tools were developed at three decision time
points: at admission to the critical care unit, at 24 h fol-
lowing admission, and at the end of calendar day 3 fol-
lowing admission. The final model at admission to the
critical care unit had fair discrimination (c index ~0.7).
When additional information from the first 24 h follow-
ing admission was added, discrimination improved (c
index ~0.8) and this level of discrimination was main-
tained at the end of calendar day 3. When clinical deci-
sion rules were defined based on cut-points of predicted
risk at the end of calendar day 3, the performance of
these rules was similar to the best performing rule from
the literature.
The major strength of the FIRE Study is the huge sam-
ple size of admissions to a large number of critical care
units across the UK, providing extremely representative
and generalisable results. The definition of Candida IFD
was chosen to be consistent with current international
consensus definitions and was carefully validated. How-
ever, despite the huge sample size, the low rate of Can-
dida IFD observed (although clearly good for patients)
made robust statistical modelling challenging. The ob-
served rate of Candida IFD was approximately half that
anticipated from the literature and consequently the
resulting models had a lower number of events per vari-
able than ideal, which may have contributed to the drop
in model performance when assessed in the validation
Candida IFD
359 (0.6%)
Candida albicansa
235 (65%)
Non-albicans Candida
sppa
110 (31%)
Candida glabrata 
62 (17%)
Candida parapsilosis
10 (3%)
Candida tropicalis 
10 (3%) 
Candida dubliniensis
4 (1%)
Candida inconspicua
2 (1%)
Candida krusei 
2 (1%)
Candida lusitaniae
2 (1%)
Candida guillermondii
1 (<1%)
Candida kefyr
1 (<1%)
Candida nivariensis
1 (<1%)
Non-albicans Candida
spp not determined 
16 (4%)
Candida spp not 
determineda
18 (5%)
Fig. 2 Organogram of Candida species causing invasive
fungal disease
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samples. Model performance was worst when applied in
the geographical validation sample, despite a similar rate
of Candida IFD, suggesting that particular care should
be taken in transferring the models to different geo-
graphical settings. A further potential limitation is the
reliance on routinely available data – for example, the
definition of Candida colonisation was based on samples
sent for microbiological evaluation in normal clinical
practice, and we did not specify any particular screening
schedule. This may contribute to variation across critical
care units, and therefore to how well the models vali-
dated in external data.
The rate of candidaemia in the present study, at 3.3
per 1000 admissions, is similar to other reports from
European critical care units [18–20]. A previous
hospital-wide surveillance from six sentinel hospitals
in the UK identified that 45 % of candidaemia was
reported from the critical care unit, corresponding to
an incidence of 7.4 per 1000 admissions [21]. A pro-
spective study in 24 French critical care units demon-
strated a candidaemia incidence of 6.7 per 1000
admissions [22].
Table 1 Case mix of admissions by invasive fungal disease
subgroup
Candida
albicans IFD
Non-albicans
Candida spp. IFD
No IFD
Number of admissions 235 106 60,362
Demographics
Age (years), median
(IQR)
61 (49, 71) 62 (50, 73) 64 (48,
74)
Male sex, n (%) 123 (52.3) 60 (56.6) 33,613
(55.7)
Medical history, n (%)
Severe comorbidities
Any severe
comorbidity
34 (14.5) 27 (25.5) 10,142
(17.0)
Very severe
cardiovascular disease
2 (1.3) 4 (5.1) 1021
(2.5)
Severe respiratory
disease
5 (3.2) 1 (1.3) 1650
(4.0)
Chronic renal
disease
6 (3.8) 2 (2.6) 1122
(2.7)
Chronic liver disease 9 (5.7) 6 (7.6) 1909
(4.7)
Metastatic disease 2 (1.3) 1 (1.3) 1421
(3.5)
Haematological
malignancy
3 (1.9) 5 (6.4) 1064
(2.6)
Immunocompromised
16 (10.2) 14 (18.0) 4092
(10.0)
Diabetes mellitus 36 (15.3) 20 (18.9) 9608
(15.9)
Neutropenia 7 (3.7) 2 (2.5) 930
(1.8)
Surgery within up to 7 days
prior to admission, n (%)
Emergency/urgent 91 (38.7) 29 (27.4) 13,127
(21.7)
Scheduled/elective 27 (11.5) 15 (14.2) 14,987
(24.8)
No surgery 117 (49.8) 62 (58.5) 32,230
(53.4)
Acute severity of illness, mean (SD)
APACHE II Score 19.0 (6.6) 19.6 (7.5) 16.0
(7.0)
ICNARC Physiology
Score
23.1 (8.8) 22.4 (9.2) 17.3
(9.3)
Primary reason for admission
to the critical care unit, n (%)
Medical 126 (51.3) 60 (62.5) 32,114
(52.2)
Respiratory 52 (22.4) 24 (23.1) 12,022
(21.0)
Cardiovascular 28 (12.1) 11 (10.6) 5622
(9.8)
Gastrointestinal 15 (6.5) 13 (12.5) 2519
(4.4)
Table 1 Case mix of admissions by invasive fungal disease
subgroup (Continued)
Neurological 6 (2.6) 1 (1.0) 4697
(8.2)
Other 25 (10.8) 11 (10.6) 7254
(12.7)
Surgical 118 (50.2) 44 (41.5) 28,131
(46.6)
Cardiovascular 76 (32.8) 37 (35.6) 13,280
(23.2)
Gastrointestinal 13 (5.6) 5 (4.8) 4201
(7.3)
Other 17 (7.2) 2 (1.9) 7601
(13.3)
Mortality, deaths (%)
Critical care unit
mortality
82 (34.9) 30 (28.3) 10,047
(16.6)
Acute hospital
mortality
93 (49.5) 42 (47.7) 13,926
(24.5)
Length of stay (days), median (IQR)
Critical care unit stay 12 (6, 24) 11 (5, 25) 2 (1, 5)
Unit survivors 12 (6, 25) 12 (6, 26) 2 (1, 5)
Unit non-survivors 12 (7, 23) 10 (3, 25) 2 (1, 6)
Acute hospital stay 33 (15, 58) 40 (20, 73) 13 (6,
27)
Acute hospital
survivors
48 (31, 79) 51 (34, 82) 14 (7,
29)
Acute hospital non-
survivors
19 (11, 42) 29 (10, 63) 8 (2, 19)
SD standard deviation, IQR interquartile range
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The distribution of Candida species in the present study
is also similar to that of other critical care units in Western
Europe [20]. A retrospective analysis of the EPIC II study,
examining Candida bloodstream infections in 14,414 pa-
tients to 1265 critical care units in 76 countries, demon-
strated varying proportions of Candida albicans and non-
albicans Candida spp. infections [23]. Seventy two percent
of the Candida infections in Western European units were
due to Candida albicans, as compared to 66 % in the
present study and 79 % in the previous UK sentinel hospital
study [21]. Variations in proportions of non-albicans Can-
dida spp infections may be due to differential use of flucon-
azole prophylaxis and subsequent emergence of resistant
strains [1]. An analysis of Candida isolates reported to the
Communicable Disease Surveillance Centre from England
and Wales between 1990 and 1999 found that Candida
albicans was responsible for 60 % of all clinically significant
isolates [24]. Annual reporting between 1990 and 1999
showed increasing rates of reported Candida species. How-
ever, more recent data from the Health Protection Agency
have shown a decline in both the total number of Candida
bloodstream infections and the proportion of these due to
Candida albicans (51 % in 2010) [25].
A recent systematic review of the literature, conducted as
part of the FIRE Study [5], identified only one previous
study with the explicit aim of developing a risk model for
Table 2 Final risk models at admission, 24 h and end of calendar day 3
Admission model 24-h model End of calendar day 3 model
Admission for pre-surgical preparation 5.01 (2.23, 11.26) – –
Surgery within 7 days prior to admission a:
Elective/scheduled – no unexpected complications b 1
Elective/scheduled – unexpected complications b 2.51 (0.89, 7.06) – –
Emergency/urgent 3.61 (2.17, 6.01) – –
No surgery 5.59 (2.91, 10.75) – –
Surgery within 7 days prior to admission c:
Elective/scheduled 1 –
Emergency/urgent – 2.44 (1.28, 4.63) –
No surgery – 2.43 (1.12, 5.28) –
Pancreatitis 4.00 (1.75, 9.15) 3.38 (1.34, 8.56) 3.01 (1.33, 6.85)
Number of central venous catheters:
None 1 1 1
1 1.49 (1.04, 2.12) 3.87 (1.53, 9.78) 3.65 (1.10, 12.05)
2 or more 4.16 (1.81, 9.60) 13.53 (5.45, 33.60) 14.79 (4.44, 49.26)
Number of drains:
None 1 1 1
1–3 1.90 (1.23, 2.93) 2.04 (1.41, 2.94) 1.93 (1.26, 2.95)
4 or more 5.12 (1.30, 20.10) 8.05 (2.35, 27.59) 7.61 (2.61, 22.2)
Enteral feeding tube in place 1.52 (1.04, 2.21) – –
Lowest SBP (first 24 h) < 90 mmHg – 1.73 (1.21, 2.46) –
Highest heart rate (first 24 h)≥ 100 min−1 – 2.35 (1.47, 3.74) 2.20 (1.24, 3.89)
Number of samples positive for fungal colonization a:
None or 1 1 – –
2 or more 7.84 (1.54, 39.76) – –
Number of samples positive for fungal colonization c:
None – 1 1
1 or more – 6.47 (4.26, 9.84) 8.21 (4.11, 16.39)
Values are odds ratio (95 % confidence interval). SBP systolic blood pressure
aFor admission model
bExamples indicative of complications in surgery include: simple surgery with unexpected blood loss (requiring transfusion); unexpected spillage/contamination
during surgery; unexpected adhesions making surgery more complex than expected; surgery being far bigger, or lasting far longer than expected
cFor 24-h/end of calendar day 3 model
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IFD, the “Candida score” [8]. The Candida score was devel-
oped in a cohort of 1699 patients admitted to 73 critical
care units in Spain and has subsequently been externally
validated among 1107 patients admitted to 36 critical care
units in Spain, Argentina and France [26]. There are sub-
stantial differences between the rationale and approach of
the Candida score and the FIRE Study. The Estudio de Pre-
valencia de Candidiasis (EPCAN) project, from which the
Candida score was developed, recruited only patients stay-
ing at least 7 days in the critical care unit, and the Candida
score was developed using only those diagnosed with
colonisation by Candida species at any time during the
critical care unit stay. The FIRE Study demonstrated
that the risk factors, and the strength of their associ-
ation with Candida IFD, varied between admission to
the critical care unit and the end of calendar day 3. A
model developed using data from later in the critical
care unit stay may therefore not accurately reflect risk
earlier in the stay, limiting the usefulness of the Candida
score for making early decisions regarding antifungal
prophylaxis. Similarly, the comparison of clinical deci-
sion rules based on the FIRE Study models with existing
rules was limited to the decision time point at the end
of calendar day 3 as all previous clinical decision rules
have been based solely on data from patients staying at
least 3 days [6, 7].
Conclusion
In summary, incidence of Candida IFD in UK critical
care units in this study was consistent with reports from
other European epidemiological studies, but lower than
that suggested by previous hospital-wide surveillance in
the UK during the 1990s. Risk modeling using classical
statistical methods produced relatively simple risk
Table 4 Performance of clinical decision rules at the end of calendar day 3 following admission to the critical care unit in the full
validation sample
Rule Percentage ‘high risk’ Sensitivity (95 % CI) Specificity (95 % CI) PPV (95 % CI) NPV (95 % CI)
FIRE Study
F1 27.1 54.1 (36.9, 70.5) 73.0 (72.0, 73.9) 0.87 (0.53, 1.34) 99.7 (99.6, 99.8)
F2 15.7 40.5 (24.8, 57.9) 84.5 (83.7, 85.2) 1.13 (0.63, 1.85) 99.7 (99.5, 99.8)
F3 6.4 24.3 (11.8, 41.2) 93.6 (93.1, 94.2) 1.65 (0.76, 3.11) 99.6 (99.5, 99.8)
Ostrosky-Zeichner et al., 2007 [6]
OZ1 58.5 86.5 (71.2, 95.5) 41.6 (40.5, 42.7) 0.64 (0.44, 0.91) 99.9 (99.7, 100)
OZ2 43.4 81.1 (64.8, 92.0) 56.7 (55.7, 57.8) 0.81 (0.55, 1.16) 99.9 (99.7, 99.9)
OZ3 21.1 51.4 (34.4, 68.1) 79.1 (78.2, 79.9) 1.06 (0.64, 1.65) 99.7 (99.6, 99.8)
Paphitou et al., 2005 [7]
P1 29.0 43.2 (27.1, 60.5) 71.0 (70.1, 72.0) 0.65 (0.37, 1.05) 99.7 (99.5, 99.8)
P2 83.2 97.3 (85.8, 99.9) 16.8 (16.0, 17.7) 0.51 (0.36, 0.71) 99.9 (99.6, 100)
P3 23.3 43.2 (27.1, 60.5) 76.8 (75.9, 77.7) 0.81 (0.46, 1.31) 99.7 (99.5, 99.8)
CI confidence interval, NPV negative predictive value, PPV positive predictive value
Table 3 Measures of model performance in the development and validation samples
Measure Development sample Validation samples
Original Optimism Adjusted a Random Temporal Geographical Full
Admission model
c index 0.705 0.688 0.721 0.650 0.640 0.655
Brier’s score 0.0040 0.0041 0.0026 0.0043 0.0040 0.0038
24-h model
c index 0.824 0.810 0.840 0.759 0.650 0.732
Brier’s score 0.0038 0.0038 0.0019 0.0042 0.0044 0.0037
End of calendar day 3 model
c index 0.835 0.825 0.803 0.720 0.661 0.709
Brier’s score 0.0050 0.0050 0.0026 0.0049 0.0048 0.0043
aOptimism adjusted using bootstrapping
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models, and associated clinical decision rules, that pro-
vided acceptable discrimination for identifying patients
at ‘high risk’ of Candida IFD.
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